These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11920393)

  • 1. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies.
    Vassilopoulos D; Calabrese LH
    Arthritis Rheum; 2002 Mar; 46(3):585-97. PubMed ID: 11920393
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus-induced vasculitis: therapeutic options.
    Cacoub P; Terrier B; Saadoun D
    Ann Rheum Dis; 2014 Jan; 73(1):24-30. PubMed ID: 23921995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Sene D; Limal N; Piette JC
    J Rheumatol; 2005 Nov; 32(11):2078-82. PubMed ID: 16265682
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.
    Ramos-Casals M; Trejo O; García-Carrasco M; Font J
    Rheumatology (Oxford); 2003 Jul; 42(7):818-28. PubMed ID: 12730523
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of chronic hepatitis C virus infection by cyclophosphamide in a patient with cANCA-positive vasculitis.
    Arend SM; Hagen EC; Kroes AC; Bruijn JA; van der Woude FJ
    Nephrol Dial Transplant; 1995; 10(6):884-7. PubMed ID: 7566624
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical guidelines of diagnosis and treatment of hepatitis C].
    Rev Gastroenterol Mex; 2007; 72(2):177-91. PubMed ID: 17966381
    [No Abstract]   [Full Text] [Related]  

  • 7. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
    Farrell GC
    J Gastroenterol Hepatol; 2007 May; 22(5):607-10. PubMed ID: 17444844
    [No Abstract]   [Full Text] [Related]  

  • 8. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
    Guillevin L
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute hepatitis C: current status and remaining challenges.
    Santantonio T; Wiegand J; Gerlach JT
    J Hepatol; 2008 Oct; 49(4):625-33. PubMed ID: 18706735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?
    Ciesek S; Manns MP; Wedemeyer H
    Minerva Gastroenterol Dietol; 2007 Dec; 53(4):337-50. PubMed ID: 18043552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive therapy for vasculitis.
    Hall S; Conn DL
    Curr Opin Rheumatol; 1995 Jan; 7(1):25-9. PubMed ID: 7536437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryofibrinogen in patients with hepatitis C virus infection.
    Delluc A; Saadoun D; Ghillani-Dalbin P; Sene D; Piette JC; Cacoub P
    Am J Med; 2008 Jul; 121(7):624-31. PubMed ID: 18589059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C infection with false negative serology in a patient with mixed cryoglobulinemic vasculitis].
    Tini GM; Wüscher V; Jeker R
    Dtsch Med Wochenschr; 2007 Mar; 132(12):616-8. PubMed ID: 17357905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological interactions in co-infected patients].
    Jáuregui Rueda H; Toibaro J
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S64-7; discussion S74-82. PubMed ID: 16862866
    [No Abstract]   [Full Text] [Related]  

  • 16. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.
    Wiesner RH; Sorrell M; Villamil F;
    Liver Transpl; 2003 Nov; 9(11):S1-9. PubMed ID: 14586888
    [No Abstract]   [Full Text] [Related]  

  • 17. Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects.
    Gish RG
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):xxiii-xxiv. PubMed ID: 15081104
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of type C fulminant and subfulminant hepatitis--featuring antiviral and immunosuppressive treatment].
    Yoshiba M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):549-56. PubMed ID: 7563822
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacotherapy of hepatitis C virus infection: a brief review.
    Quan DJ
    Nephrol Nurs J; 2009; 36(3):333-7. PubMed ID: 19588704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future therapies for hepatitis C.
    Pawlotsky JM; Gish RG
    Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.